Novartis Ag (NYSE:NVS) shares traded 2.24% up during most recent session to reach at the closing price of $80.48. The stock exchanged hands 3.17 Million shares versus average trading capacity of 2.51 Million shares, yielding a market cap of $190.35 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $85.75 within the next 52-weeks. The mean target projections are based on 4 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Novartis Ag (NYSE:NVS) high price target of $92 and with a conservative view have low price target of $80.

Cowen & Co. “Downgrades” Novartis Ag (NYSE:NVS) in a research note issued to investors on 4/05/17 to Market Perform with price target of $77.

Additionally on 1/11/17 Credit Suisse “Downgrades” Novartis Ag (NYSE:NVS) to Neutral setting price target and on 1/03/17 JP Morgan “Downgrades” the stock to Neutral. Furthermore on 11/10/16 Argus Research “Upgrades” the stock to Buy.

On the other hand the company has Relative Strength Index (RSI 14) of 80.31 along with Average True Range (ATR 14) of 0.79, Consequently Novartis Ag (NYSE:NVS)’s weekly and monthly volatility is 0.74%, 0.73% respectively. The company’s beta value is at 0.78.

In terms of Buy, Sell or Hold recommendations, Novartis Ag (NYSE:NVS) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Analysts who have weighed in on projected earnings growth are expecting that Novartis Ag (NYSE:NVS) will report earnings of $1.18 for the current quarter on or around 7/18/17, however the company’s high EPS estimates are $1.22 and low estimates are $1.14. However the company reported $1.23 earnings per share for the same quarter during last year.

Previously Novartis Ag (NYSE:NVS) reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.02. The company posted an earnings surprise of 1.8%.

While considering growth estimates of the company, it has next quarter growth estimates of -1.6% whereas during current quarter it has -4.1% estimations over growth, comparing to the estimations of 0.2% during current year and 10% for next year. Past 5 years growth of Novartis Ag (NYSE:NVS) observed at -2.81%, looking forward for the next 5 years it has a strong prediction of 5.52% over growth.

Novartis Ag (NYSE:NVS)’s revenue estimates for the current quarter are $12.25 Billion according to 6 number of analysts, for the current quarter the company has high revenue estimates of $12.4 Billion in contradiction of low revenue estimates of $12.11 Billion. For the current year the company’s revenue estimates are $48.29 Billion compared to low analyst estimates of $47.2 Billion and high estimates of $49.89 Billion according to 22 number of analysts.

Currently Novartis Ag (NYSE:NVS)’s shares owned by insiders are 9.3%, whereas shares owned by institutional owners are 11.1%. However the six-month change in the insider ownership was recorded 0.2%, as well as three-month change in the institutional ownership was recorded 1.87%.

Novartis Ag (NYSE:NVS) 52-week high price stands80.64 and low price stands64.58, its price distance from 52-week high is -0.2% while its distance from 52-week low price is 24.62%. The stock hit its 52-week high on 07/22/16, and 52-week low on 12/08/16. The company’s trailing twelve month income is 6.37 Billion dollars and is paying 3.38% dividend yield annually.

Novartis Ag (NYSE:NVS)’s trailing twelve month revenues are $49.41 Billion, whereas its price to sales ratio for the same period is 4.16. Its book value per share for the most recent quarter is $28.49 while its price to book ratio for the same period is 2.82, as for as the company’s cash per share for the most recent quarter is $0, however its price to cash per share ratio for the same period is 0. The stock has 5 year expected PEG ratio of 5.49 whereas its trailing twelve month P/E ratio is 30.3.